Neuroleptic-induced mitochondrial enzyme alterations in the rat brain

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 1, 1997, Pages 261-267

  Prince, Jonathan A ^a   Yassin, Mohammed S ^a   Oreland, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CLOZAPINE; CYTOCHROME C OXIDASE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX IV; MALE; MITOCHONDRIA; MONOAMINE OXIDASE; NADH, NADPH OXIDOREDUCTASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030899962     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. ANDREASSEN, O. A. AND JORGENSEN, H. A.: The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rat: Implications for tardive dyskinesia? Psychopharmacology 119: 474-476, 1995.
2. BEAL, M. F., HYMAN, B. T. AND KOROSHETZ, W.: Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 16: 125-131, 1993.
3. BURKHARDT, C., KELLY, J. P., LIM, Y. H., FlLLEY, C. M. AND PARKER, W. D.: Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 33: 512-517, 1993.
4. CAVALIER, L., JAZIN, E., ERIKRSON, I., PRINCE. J., BAVE, B., ORELAND, L. AND GYLLENSTEN, U.: Decreased cytochrome-c oxidase activity and lack of age related accumulation of mtDNA in the brains of schizophrenics. Genomics 29: 217-228, 1995.
5. CHIBA, K., TREVOR, A. J. AND CASTAGNOLI, N.: Metabolism of the neurotoxic tertiary amine MPTP by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120: 574-578, 1984.
6. COHEN, B. M., TSUNEIZUMI, T., BALDESSARINI, R. J., CAMPBELL, A. AND BABB, S. M.: Differences between antipsychotic drugs in persistence of brain levels and behavioural effects. Psychopharmacology 108: 338-344, 1992.
7. ERESHEVSKY, L., JANN, M. W., SAKLAD, S. R. AND DAVIS, K. L.; Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J. Clin. Psychiatry 47(Suppl. 9): 6-15, 1986.
8. FANG, J., YU, P. H., GORROD, J. W. AND BOULTON, A. A.: Inhibition of monoamine oxidases by haloperidol and its metabolites: Pharmacological implications for the chemotherapy of schizophrenia. Psychopharmacology 118: 206-212 1995.
9. FULLER, R. W. AND HEMRICK-LUECKE, S. K.: Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Pharmacol. Exp. Ther. 232: 696-701, 1985.
10. GLTH, P. S. AND SPRITES, M. A.: The phenothiazine tranquilizers: Biochemical and biophysical actions. Int. Rev. Neurobiol. 7: 231-278, 1964.
11. GRENELL, R. G., MENDELSON, J. AND MCELROY, W. D.: Effects of chlorpromazine on metabolism in central nervous system. A. M. A. Arch. Neurol. Psychiat 73: 347-351, 1955.
12. HALLMAN, J., ORELAND, L., EDMAN, G. AND SCHALLING, D.: Thrombocyte monoamine oxidase activity and personality traits in women with severe premenstrual syndrome. Acta Psychiatr. Scand. 76: 225-234, 1987.
13. HEVNER, R. F., DUFF, R. S. AND WONG-RILEY, M. T. T.: Coordination of ATP production and consumption in brain: parallel regulation of cytochrome oxidase and Na +,K+-ATPase. Neurosci. Lett. 138: 188-192, 1992.
14. HEVNER, R. F. AND WONG-RILEY, M. T. T.: Mitochondrial and nuclear gene expression for cytochrome oxidase subunits are disproportionately regulated by functional activity in neurons. J. Neurosci. 13: 1805-1819, 1993.
15. HUBBARD, J. W., GAMES, D. AND MIDHA, K. K.: Prolonged pharmacological activity of neuroleptic drug. Arch. Gen. Psychiatry 44: 99-100, 1987.
16. KLUSHNIK, T. P., SPUNDE, A., YAKOVLEV, A. G., KHUCHUA, A. A., SAKS, V. A. AND VARTANYAN, M. E.: Intracellular alterations of the creatine kinase isoforms in brains of schizophrenic patients. Mo. Chem. Neuropathol. 15: 271-280, 1991.
17. KORPI, E. R., KLEINMAN, J. E., COSTAKOS, D. T., LINNOILA, M. AND WYATT, R. J.: Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiat. Res. 11: 259-268, 1984.
18. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein Measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-75, 1951.
19. MARKWELL, M. A. C., MAAS, S. M., BIEBAR, L. L. AND TOLBERT, N. E.: A modification of the Lowry procedure to simplify protein determination in membrane and in protein samples. Anal. Biochem. 87: 206-211, 1978.
20. MIDHA, K. K., HAWEH, E. M., HUBBARD, J. W., KORCHINSKI, E. D. AND MCKAY, G.: Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients. Psychopharmacology 96: 206-211, 1988.
21. MIZUNO, Y., OHTA, S., TANAKA, M., TAKAMIYA, S., SUZUKI, K., SATO, T., OYA, H., OZAWA, T. AND KAGAWA, Y.: Deficiencies in complex I subunits of respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163: 1450-1455, 1989.
22. MORACZEWSKI, A. AND ANDERSON, R. C.: The determination by quantitative histochemistry of the effect of phenothiazines on brain cytochrome c oxidase activity. J. Histochem. Cytochem. 14: 64-76, 1966.
23. NIKLAS, W. J., VYAS, I. AND HEIKKILA, R. E.: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridinium, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36: 2503-2508, 1985.
24. PARKER, W. D., BOYSON, S. J. AND PARKS, J. K.: Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26: 719-723, 1989.
25. RIACHI, N. J., DIETRICH, W. D. AND HARIK, S. I.: Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier. Brain Res. 533: 6-14, 1990.
26. ROLLEMA, H., SKOLNIK, M., D'ENGELBRONNER, J., IGARASHI, K., USUKI, E. AND CASTAGNOLI, N.: MPP+-like neurotoxicity of a pyridium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268: 380-387, 1994.
27. SUBRAMANYAM, B., ROLLEMA, H., WOOLF, T. AND CASTAGNOLI, N.: Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun. 166: 238-244, 1990.
28. SUBRAMANYAM, B., WOOLF, T. AND CASTAGNOLI, N.: Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem. Res. Toxicol. 4: 123-128, 1991.
29. TSANG, D., HO, K. P. AND WEN, H. L.: Ontogenesis of multiple forms of monoamine oxidase in rat brain regions and liver. Dev. Neurosci. 8:243-50, 1986.
30. VAN DER KROGT, J. A., VAN VALKENBURG, C. F. M. AND BELFROID, R. D. M.: Rat brain monoamine oxidase activity is not affected by repeated administration of haloperidol. J. Pharm. Pharmacol. 34: 529-531, 1982.
31. VOLAVKA, J. AND COOPER, T. B.: Review of haloperidol blood level and clinical response: Looking through the window. J. Clin. Psychopharmacol. 7: 25-30, 1987.
32. WALLACE, D. C.: Mitochondrial DNA sequence variation in human evolution and disease. Proc. Natl. Acad. Sci. U.S.A. 91: 8739-8746, 1994.
33. WEINBERGER, D. R., BERMAN, K. F., SUDDATH, R. AND TORREY, E. F.: Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am. J. Psychiatry 149: 890-897, 1992.
34. WHITFIELD, C. D., BOSTEDOR, R., GOODRUNT, D., HAAK, N. AND CHU, E. H. Y.: Hamster cell mutants unable to grow on galactose and exhibiting an overlapping complementation pattern are defective in the electron transport chain. J. Biol. Chem. 256: 6651-6656, 1981.
35. WIESEL, F. A.: Glucose metabolism in psychiatric disorders: How can we facilitate comparisons among studies? J. Neural. Trans. Suppl. 37: 1-18, 1992.
36. WONG-RILEY, M.: Cytochrome oxidase: An endogenous metabolic marker for neuronal activity. TINS 12: 94-101, 1989.
37. WONG-RILEY, M. AND CARROL, E. W.: Effect of impulse blockage on cytochrome oxidase activity in monkey visual system. Nature 307: 262-264, 1984.
38. WYATT, R. J. AND MURPHY, D. L.: Low platelet monoamine oxidase activity and schizophrenia. Schizophren. Bull. 2: 77, 1976.
39. YONETANI, T. AND RAY, G.: Studies on cytochrome oxidase. J. Biol. Chem. 240: 3392-3399, 1965.
40. ZETLER, G. AND BAUMANN, G. H.: Pharmacokinetics and effects of haloperidol in the isolated mouse. Pharmacology 31: 318-327, 1985.